← SynDRA
CANAGLIFLOZIN ANHYDROUS
SynDRA canonical compound SYN0029445 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SLC5A2 |
|---|
| Mechanism of action | Sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SLC5A2
- SLC5A1
- CYP2B6
- CYP2C8
- protease
Mechanisms of action (all sources)
- Sodium/glucose cotransporter inhibitor
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- SLC5A2 MODULATOR
Drug classes
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- P-Glycoprotein Inhibitors
- Sodium-Glucose Cotransporter 2 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- canagliflozin
- invokana
- canagliflozin hemihydrate
- canagliflozin hydrate
- JNJ-28431754
- TA-7284
- Canagliflozin
- Invokana
- UNII-6S49DGR869
- JNJ 24831754ZAE
- Canagliflozin hydrate
- TA 7284
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
- CHEBI:73274
- 6S49DGR869
- (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL
- (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol
- JNJ-28431754-AAA
- INVOKAMET COMPONENT CANAGLIFLOZIN
- CANAGLIFLOZIN
- 0SAC974Z85
- JNJ 28431754
- JNJ-24831754-ZAE
- Canagliflozin Hemihydrate
- Canagliflozina
- Canagliflozine
- Canagliflozin, Anhydrous
- canagliflozinum
- RefChem:398790
- A10BK02
- DTXCID901431370
- MFCD18251436
- Canagliflozin [INN]
- C24H25FO5S
- JNJ 24831754AAA
- JNJ 24831754
- Canagliflozin (Standard)
- CANAGLIFLOZIN [MI]
Reported adverse events
- Constipation
- Infection
- Nausea
- Pollakiuria
- Polyuria
- Thirst
- Urinary tract infection
- Vulvovaginal candidiasis
- Amputation
- Abdominal pain
- Balanitis candida
- Balanoposthitis
Look up CANAGLIFLOZIN ANHYDROUS in the interactive SynDRA portal →